Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19
Isaac A. Klein(Harvard University), Ann H. Partridge(Dana-Farber Cancer Institute), Gregory J. Kirkner(Dana-Farber Cancer Institute), Michael Klompas(Brigham and Women's Hospital), Leyre Zubiri(Massachusetts General Hospital), Shoshana M. Rosenberg(Dana-Farber Cancer Institute), Meghan A. Baker(Brigham and Women's Hospital), Rachel Gaither(Dana-Farber Cancer Institute), Andrew J. Piper‐Vallillo(Harvard University), Aditya Bardia(UCLA Health), Kerry L. Reynolds(Massachusetts General Hospital), Martha Wadleigh(Dana-Farber Cancer Institute), Chanu Rhee(Brigham and Women's Hospital), Eric P. Winer(University of Vermont), Rachel Rosovsky(Harvard University), Xīn Gào(Qingdao University), Camille N. Kotton(Harvard University), Hannah Freeman(Dana-Farber Cancer Institute), Genevieve M. Boland(Harvard University)
Cited by 8
Related Papers
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
|Critical Care Medicine|2021|2.8k